Skip to main content
PMC home page
Frontiers in Cell and Developmental Biology logoLink to Frontiers in Cell and Developmental Biology
. 2022 Feb 24;10:835675. doi: 10.3389/fcell.2022.835675

Skin Immunosenescence and Type 2 Inflammation: A Mini-Review With an Inflammaging Perspective

Bangtao Chen 1, Jing Yang 1, Yao Song 2, Daojun Zhang 2, Fei Hao 2,*
PMCID: PMC8908007  PMID: 35281103

Abstract

Skin-resident stromal cells, including keratinocytes, fibroblasts, adipocytes, and immune cells including Langerhans cells, dendritic cells, T cells, and innate lymphoid cells, and their functional products work in concert to ensure the realization of skin barrier immunity. However, aging-induced immunosenescence predisposes the elderly to pruritic dermatoses, including type 2 inflammation-mediated. Inflammaging, characterized by chronic low level of pro-inflammatory cytokines released from senescent cells with the senescence-associated secretory phenotype (SASP), may drive immunosenescence and tangle with type 2 inflammatory dermatoses. The present mini-review summarizes current evidence on immunosenescence and type 2 inflammation in the skin and further focuses on future needs from an inflammaging perspective to clarify their complexity.

Keywords: immunosenescence, inflammaging, skin aging, dermatosis, mini-review and challenges

Introduction

The skin is the largest active immune organ, covering the body’s outermost layer and performing the function of resisting external stimulus, thus maintaining skin homeostasis. Skin barrier inevitably undergoes characteristically immunological declines with advancing age, termed skin immunosenescence. Higher incidences of many dermatoses such as infectious diseases, non-communicable autoimmune diseases, and cutaneous malignancies, and more pathological states such as unspecific itchiness and delayed wound healing are observed in the elderly alongside immunosenescence (Farage et al., 2009). Senescent cells remain senescence-associated secretory phenotype (SASP) secreting low-level pro-inflammatory cytokines including CRP, IL-1β, IL-6, and TNF-α, which is usually referred to inflammaging (Lopes-Paciencia et al., 2019; Fitsiou, et al., 2021). Type 2 inflammatory dermatosis such as atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP) frequently affect the elderly and are presumed to be correlated with skin immunosenescence. Moreover, the diseases affecting the elderly are prone to more severity, therapeutic resistance, and longer duration. The current mini-review focuses on skin immunosenescence and type 2 inflammation and present future needs from an inflammaging perspective, promising better management of type 2 inflammatory dermatosis in the elderly (Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Current evidence of immunosenescence in aged skin with or without type 2 inflammation dermatoses. Type 2 inflammation dermatoses such as AD, CSU, and BP are driven by key cytokines including IL-25, IL-33, and TSLP released from damaged epithelium and LCs/DCs (right column). Skin barrier inevitably undergoes characteristically immunological changes (skin immunosenescence) during aging in healthy individuals (left column) and in individuals affected by type 2 inflammation dermatoses. Inflammaging that is characterized by low level of pro-inflammatory cytokines including CRP, IL-1β, IL-6, and TNF-α produced by senescent skin cells may be in complex interaction with the two conditions. No., number; KCs, keratinocytes; FBs, fibroblasts; LCs, Langerhans cells; DCs, dendritic cells; MCs, mast cells; ILC2, innate lymphoid cell 2; Tm, memory T cells; Ig, immune globulin; MMP-12, matrix metalloproteinase 12; ASST, autologous serum skin test; TSLP, thymic stromal lymphopoietin; STAT, signal transducer and activator of transcription; IL1RL1, IL-1 receptor-like 1; AD, atopic dermatitis; CSU, chronic spontaneous urticaria; BP, bullous pemphigoid.

Skin Barrier Immunity

Skin-resident stromal cells, including keratinocytes, fibroblasts, and adipocytes, and immune cells including Langerhans cells (LCs), dendritic cells (DCs), T cells, and innate lymphoid cells (ILCs) together with their functional products ensure the realization of skin barrier immunity. The cells mentioned above work synergistically or antagonistically upon harmful environmental exposures challenge, leading to reinforced or compromised networks protecting the skin against damage or causing dermatosis, respectively.

Stromal Cells

Epidermal keratinocytes express and secrete antimicrobial ribonuclease RNase 7 and antimicrobial peptides adrenomedullin, β-defensins, and cathelicidin upon recognizing pathogenic components via its constitutive expressions of toll-like receptors (TLRs) on the cellular surface (Miller and Modlin, 2007; Köllisch, et al., 2005). In addition, keratinocytes function in the presentation of antigen from CD4+ to CD8+ T cells and promote tissue repair via chemokine (IL-1β, IL-8, and CCL20)-mediated leukocyte recruitment during early wound healing (Black, et al., 2007; Li, et al., 2017; Sperling, et al., 2012). They also serve as key sites for UVB-catalyzed production of active vitamin D3 (Zbytek, et al., 2008). Dermal fibroblasts are not only key to supporting wound healing through the secretion and remodeling of extracellular matrix (ECM) but also essential for facilitating innate immune response to microbial infections by secreting cytokines and chemokines with involvement of toll-like receptor activation (Ghetti, et al., 2018; Cole, et al., 2018; Haniffa, et al., 2007; Bautista-Hernández, et al., 2017). Interestingly, fibroblasts were uncovered to inhibit T-cell proliferation and induce the production of immunoregulatory cytokines such as IL-10 (Haniffa, et al., 2007). Moreover, adipocytes differentiated from dermal fibroblasts upon Staphylococcus aureus infection can also produce the antimicrobial peptide cathelicidin (Zhang, et al., 2015).

Immune Cells

LCs, the mononuclear phagocyte within the epidermis, not only produce antimicrobial peptide hBD3 and initiate a local immune response mainly by presenting antigens to T cells (Ferris, et al., 2013; Atmatzidis, et al., 2017; Pilkington, et al., 2018a), but also migrate to skin regional lymph nodes for enhancing immune response to exogenous antigens and promoting tolerance to self-antigens (West and Bennett, 2018; Atmatzidis, et al., 2017).

DCs and macrophages, the mononuclear phagocyte located in the dermis, are also the sentinels of the innate immunity working similarly to epidermal LCs. Dermal DCs comprise CD1c+ or CD141+ myeloid and plasmacytoid forms, while the latter is hardly observed in steady-state skin (Collin and Bigley, 2018). Compared with their blood counterparts, normal dermal DCs associated with T-cell proliferation displayed an activated phenotype with increased expression of co-stimulatory receptors (McLellan, et al., 1998). Dermal macrophages are specifically labeled with CD163, and the cells also contribute to wound and nerve healing by suppressing inflammation upon tissue injury (Kolter, et al., 2019).

The same as skin LC and DC, B cells found in healthy skin are integral for presenting antigen at low concentration to T cells (Geherin, et al., 2012). Moreover, skin B cells also modulate inflammation response by secreting pro- or anti-inflammatory mediators (Debes, and McGettigan, 2019).

Skin-resident T cells derived from T cells differentiated and matured in the thymus via migration through the lymphatic or circulatory system. Phenotypically, 80%–90% of the skin T-cell pool is memory T (Tm) cells, and the remaining is recirculating T cells (Nguyen, et al., 2019). Tm cells have stronger immune surveillance against reinvasions, and expressions of CD69 and CD103 on cell surface commonly characterize this type of T cells (Mackay, et al., 2013). The number of CD4+ Tm cells is three and six times that of CD8+ Tm cells in the epidermis and dermis, respectively (Watanabe, et al., 2015). With a memory skin-resident phenotype inducing immune tolerance, Foxp3+ regulatory T cells (Tregs) are in close proximity to hair follicles where skin commensal-metabolized short-chain fatty acid sodium butyrate or UVB light increases Foxp3+ expression in non-Tregs or drive Foxp3+ Tregs proliferation (Schwarz, et al., 2017; Yamazaki, et al., 2014; Scharschmidt, et al., 2017). Overall, αβ T cells dominate in the skin as in circulation (Nielsen, et al., 2017).

Cutaneous ILCs located in the epidermis and dermis are newly identified immune cells whose function is not fully understood, but influxes of ILC2 in AD and LC1/3 in psoriatic plaques were demonstrated (Brüggen, et al., 2016; Akdis, et al., 2020). Neutrophils are seldom in the skin, while they can infiltrate the skin upon exposure to a harmful stimulus (Rijken, et al., 2005). In addition, allergens or inflammatory irritants can induce the release of histamine and inflammatory mediators from cutaneous mast cells (MCs), mediating wheals and itch onset (Otsuka, and Kabashima, 2015).

Skin Immunosenescence

The skin goes roughly through stages of immaturity, maturation, and decline over lifespan as with all other organs. Although incredibly durable, aging still causes skin structure and function changes, termed skin aging. This process is usually exaggerated by extrinsic exposures such as UVR. Morphologic and related functional changes in chronologically or intrinsically aged skin were summarized in a review conducted by Zouboulis, and Makrantonaki, (2011). In particular, immunosenescence contributes to the increased susceptibility to skin disorders with malignancies, infections, and autoimmunity in the elderly. Skin immunosenescence refers to declines in function or number of all skin cells responsible for immune surveillance (Corsini, et al., 2009). Senescent cells, promoted by telomere shortening and genome instability, remain SASP secreting low level of pro-inflammatory cytokines including IL-1β, IL-6, and CRP, thus altering the skin’s microenvironment (Lopes-Paciencia, et al., 2019; Fitsiou, et al., 2021). Presumably, skin inflammaging characterized by chronic low-level inflammation is believed to be the main driver for remodeling the immunological response in senescent skin cells (Ghosh, and Capell, 2016).

Stromal Cell Senescence

Dermal senescent fibroblasts accumulated with age and displayed SASP rich, thus maintaining inflammaging phenotype (Wlaschek, et al., 2021). Such changes contribute to disruptions of collagen homeostasis, delayed wound healing, and increased likelihood of skin tumorigenesis; however, its antibacterial immunity loss caused by aging has been associated with impaired adipocyte differentiation (Zhang, et al., 2019; Wasko, and Horsley, 2019). Compared with fibroblasts, the impact of accumulated senescent keratinocytes in the epidermis on inflammaging or antibacterial immunity is limited due to its higher turnover rate (Pilkington, et al., 2021).

Immune Cell Senescence

In aged skin, decreased proliferation of in situ LC progenitors causes a reduced number of LCs, and LCs are also less able to migrate from the epidermis in response to harmful stimulus due to the declined availability of local IL-1β, which collectively contributes to impaired skin barrier integrity and diminished antimicrobial and tumor cell defense (Pilkington, et al., 2018b). In addition, LC-mediated skin barrier perturbation may facilitate the onset of skin inflammaging by initiating cytokine release from cutaneous cells (Wittmann, et al., 2014).

To some extent, the state of thymus and T cells in circulation are implicated in many dermatoses, which also reflect the profiles of skin-resident T cells. In geriatric individuals, circulating T cells in total number remain unchanged, accompanied by reduction of naive T cells due to thymic involution and increase of Tm cells since the prolonged exposure to external substances over the lifespan (Thomas, et al., 2020). However, little is known regarding the changes in skin-resident Tm cells during aging. A higher ratio of CD4+ to CD8+ T cells was found in aged skin than in young skin, indicating a more severe pro-inflammatory response phenotype (Zuelgaray, et al., 2019). Cytokines during inflammaging can be Th2 pattern dominant with an increased incidence of allergic diseases and Th1 pattern dominant with a higher frequency of chronic infections and neoplastic diseases. It was reported that Tregs numbers and immunosuppressive receptor PD-1 increased in aged skin, thus causing reactivation of infectious diseases or skewing inflammatory microenvironment by suppressing both Th1 and Th2 responses (Lages, et al., 2008). Additionally, a diminished response of T cells to specific antigens in advanced age may collectively explain why the chronic low-level inflammation characterizes the state of inflammaging (Bektas, et al., 2017).

Aging-related changes in skin B cells are similar to skin T cells except that B cells from the elderly are less efficiently stimulated. Thus, antibody generation decreases, and immune response to vaccines and antigens is weakened (Pinti, et al., 2016).

Immunosenescence and Type 2 Inflammatory Dermatosis

Type 2 inflammation phenotypes in skin and circulation are usually in traffic with each other and remain consistent. IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) released from damaged epithelium directly activate the production of IL-4, 5, 9, 13, and 31 from ILC2 and Th2 cells, thus characterizing type 2 inflammation immunity (Akdis, et al., 2020). Both IL-25 and IL-33 can activate MAPK and NK-κB signaling pathways via binding to IL-17RA/B and IL-1 receptor-like 1 (IL1RL1), respectively (Akdis, et al., 2020; Deng, et al., 2021). By activating signal transducer and activator of transcription (STAT), skin LC/DC-derived and keratinocyte-derived TSLP are critical for Th2-type immune responses and mediating pruritus exacerbation, respectively (Kim et al., 2013). In addition, humoral immunity characterized by allergen-specific antibody IgE or autoantigen-specific autoantibody IgG matured by IL-13 and IL-4 is also involved in type 2 inflammatory dermatosis such as AD, CSU, and BP (Gandhi, et al., 2016).

Atopic Dermatitis

Globally, 10% of adults and 1%–3% of elderly populations are troubled by AD (Lloyd-Lavery, et al., 2019; Williamson, et al., 2020). Moreover, the increasing predisposition of late AD development in older adults is due to exposure-induced epidermal barrier malfunction and immunosenescence-caused chronic itch in advanced age. The core of AD is skin inflammation involving IgE produced by B cells and inflammatory mediators of T-cell origin, while Th2 cytokines dominate in the inflammation milieu (Tanei, and Hasegawa, 2016; Tanei, et al., 2013). Th2/Th22 cytokines in skin increase during aging in healthy individuals, while the opposite phenomenon is observed in older AD patients (Bocheva, et al., 2021; Gittler, et al., 2012). With age progressing, Th1- and Th17-related mediators in lesioned and non-lesioned skin in individuals suffering from AD are markedly increased, as observed in healthy adults (Bocheva, et al., 2021; Gittler, et al., 2012). Zhou et al. showed that inflammatory DCs in the skin and cutaneous expression of matrix metalloproteinase 12 (MMP-12) were reduced in both affected and unaffected skin in AD with aging (Agrawal, et al., 2012; Zhou, et al., 2019). Reduction in specific and total serum IgE with aging in patients with allergic rhinitis, asthma, or insect allergy implies a decreasing proportion of extrinsic atopy among older adults; however, the association between serum IgE and aging in AD patients remains inconsistent (Zhou, et al., 2019; Mediaty, and Neuber, 2005). In addition, aging-related increment in terminal keratinocyte differentiation markers (filaggrin and loricrin) and decrement in epidermal hyperplasia markers (Ki16 and Ki67) were also observed in AD (Zhou, et al., 2019), which might be attributable to attenuation in the Th2/Th22 cytokine axes (Boniface, et al., 2005); moreover, it reveals a critical role for crosstalk between immune cell senescence and stromal cell-mediated immunity impairment in severity of geriatric AD.

Chronic Spontaneous Urticaria

Traditionally, CSU is an allergic dermatosis mediated by degranulation and histamine released from skin MCs or basophils (Bracken, et al., 2019). As mounting CSU patients show antihistamine resistance, it is supposed to be T cell-mediated with emerging evidence that concentrations of circulating cytokines released from Th1/Th2 and Th17 cells correlated positively with disease severity in our previous study (Chen, et al., 2018). Kay et al. added the finding that increased expressions of IL-25, IL-33, and TSLP in skin wheals of patients with CSU further accurately characterize the pathogenesis and categorize it as type 2 inflammatory dermatosis (Kay, et al., 2015; Vadasz, and Toubi, 2015). In retrospective investigations performed in localized areas, older CSU patients made up 9.4%–25% of the CSU population. Furthermore, fewer wheals, lower rates of ASST positivity, angioedema, and dermographism, and more comorbidities were reported in elderly patients with CSU diagnosis (Chen, et al., 2012; Magen, et al., 2013). The atypical symptoms are pertinent to aging-related immunosenescence. For one thing, stromal-cell functional impairment with aging was proved to cause a decline in MC development (Tsuboi et al., 2012). For another, skin MCs accumulated while their degranulation capability was reduced with aging. Furthermore, they re-localize to the papillary dermis, where MCs keep in closer proximity to macrophages and VIP+ nerve fibers while the association with dermal vasculature is weakened (Pilkington, et al., 2019). Unfortunately, little is known regarding alterations of number, function, and crosstalk among MCs, basophils, and T and B cells in elderly individuals with CSU.

Bullous Pemphigoid

BP, an autoimmune blistering dermatosis in the elderly mediated by IgG autoantibodies to skin hemidesmosome proteins (BP180 and/or BP230) and activation of complement component C3, is characterized by urticarial plaques, tense blisters, and intractable pruritus (Bağcı, et al., 2017). In BP development, autoreactive T cells work cooperatively. Increased circulating Th2 cells and IL-4 promote B-cell proliferation, antibody production, and immunoglobulin class-switching, while skin-resident Th17 cells and IL-17 activate local neutrophil-mediated inflammatory response, thus causing tissue damage (Fang, et al., 2020; Boehncke, and Brembilla, 2019). In recent studies, specific anti-BP180/230 IgE in BP were detected by immunoassays; furthermore, positive associations between IgE content and Th2 cell-specific cytokines IL-4/-13 and symptomatic disease phenotypes were shown (Cozzani, et al., 2018; Messingham, et al., 2019). The finding that IgE-driven BP promises the therapeutic regimes using Th2 inhibitors in BP-affected frail patients with good safety and ideal effectiveness. It was reported that disease clearance or satisfactory response was achieved in 12 of 13 BP patients (an average age of 76.8 years) treated with Dupilumab, an IL-4 receptor alpha antagonist with the property of inhibiting IL-4/-13 signaling and IgE secretion (Abdat, et al., 2020). Immunosenescence-related aging is conceivably responsible for the increased incidence of BP in the elderly (Pietkiewicz, et al., 2016; Yaar, and Gilchrest, 1987). However, fewer studies focus on the effect of immunosenescence or inflammaging on pathophysiological characteristics of BP, and only a meeting paper uncovered increased markers of immunosenescence in BP patients (Noe, et al., 2015).

Future Needs

Too many questions regarding skin immunosenescence and type 2 inflammations need to be answered.

Firstly, existing studies fail to provide direct and strong evidence for the involvement of immunosenescence in type 2 inflammatory dermatosis. Distinctive clinical features and incidences of type 2 inflammatory dermatosis between the young and the elderly are observed, and the difference is often thought to be caused by aging-related changes including immunosenescence, but direct evidence remains insufficient. As evidenced by the recent discovery of TH2-interacting fascial fibroblasts (TIFFs) in mouse and human skin, skin-resident or -infiltrating immune cells and stromal cells are complexly interacting and influence each other throughout life (Boothby, et al., 2021). They undergo structural and functional alterations simultaneously, but overall, inflammaging phenotype characterizes the skin microenvironment during normal aging. In aged individuals with type 2 inflammatory dermatosis, the relationship of the skin microenvironment with inflammaging and changes to cutaneous immunity is more complex due to repeated scratching caused by uncontrolled itchiness. Therefore, it is far-fetched to conclude that a specific pathophysiological change is independently caused by a specific senescent cell alone or the disease itself. In particular, further exploration of the associations between remolding of senescent fibroblast-released ECM and type 2 inflammation in aged skin will provide new insights into strategies used in related dermatosis.

Secondly, could skin immunosenescence contribute to systemic immunosenescence or vice versa from the perspective of inflammaging? A shining shared feature of type 2 inflammatory dermatoses in the young or elderly is the presence of Th2 cytokines in circulation and the lesions, and inflammation state in lesions is proposed to be orchestrated by systemic inflammation phenotype (Rafei-Shamsabadi, et al., 2019; Pezzolo and Naldi, 2020). Given this, the reverse argument is worth further considering, especially in the elderly with impaired skin barrier as epidermal abnormality in AD has been proposed to drive systemic inflammation (Elias and Steinhoff, 2008). Hu et al. showed that tape stripping-induced epidermal dysfunction led to an age-associated increase in levels of circulating inflammatory cytokines in mice (Hu, et al., 2017), and Ye et al. also provided the evidence that correction of epidermal function by emollient lowered systemic inflammaging measured by circulating levels of IL-6 and TNF-α in chronically aged human (Ye, et al., 2019). These studies may collectively support the thesis that epidermal dysfunction-mediated immunosenescence could contribute to the onset or severity of type 2 inflammatory dermatosis with systemic inflammation involved in the elderly. However, more investigations are warranted to confirm the thesis by untangling their cause and effect.

On the contrary, the complexity of systemic and tissue inflammaging can also be witnessed in the efficacy of anti-inflammaging agents. Anti-inflammaging drugs indeed hold promise for increasing healthy aging, and much effort aimed at slowing aging by targeting inflammaging has been conducted (Partridge, et al., 2020; Suggs, et al., 2014). Rapamycin, metformin, and various botanicals showed delaying the aging process by inhibiting cellular senescence dependent or independent of their anti-inflammaging properties (Partridge, et al., 2020; Suggs, et al., 2014). For example, topical rapamycin, an FDA-approved agent, showed no beneficial effects in inflammaging (Correia-Melo, et al., 2019) but improved histological appearance of aged skin by reducing fibroblast senescence and increasing collagen VII (Chung, et al., 2019; Qin, et al., 2018). As such, the correction of the impaired skin barrier by anti-inflammaging agents preventing or mitigating systemic inflammaging is meaningful and easily articulable.

Thirdly, other intrinsic drivers of skin immunosenescence or inflammaging should also be identified in terms of the organism as a whole. Changes to gut and skin microbiota, mitochondrial damage-associated molecular patterns (DAMPs), abnormal activity of coagulation and fibrinolysis, complements, and vitamin D3 deficiency during aging have also been linked with type 2 inflammation dermatoses (Nakahara, et al., 2021; Sánchez-Borges et al., 2018; Hashimoto, et al., 2020). Whether the correction of abnormalities benefits improvement of related dermatoses through immunosenescence retardation remains to be further investigated.

Lastly, skin immunosenescence can be partly determined with flow cytometry and immunohistochemistry by frequency assessments of senescent immune cells due to their end-stage differentiated and cell-specific markers; however, no techniques are available for assessing inflammaging caused by indicated senescent cells in vivo. It appears that all immune- or non-immune-senescent cells possess SASP properties releasing low levels of IL-1β, IL-6, TNF-α, and CRP. These pro-inflammation mediators that can shuttle through skin and circulation are non-specific for SASP-centered inflammaging. More than that, they can be transiently modulated by acute or persistently modulated by chronic inflammatory diseases, including type 2 inflammation dermatoses in young or older populations. Meanwhile, immunosenescence and inflammaging in the skin are mutually regulated, but they do not always parallel, especially for senescent cells in the end stage. Herein, screening of reasonable indicators for inflammaging in the elderly with and/or without inflammation dermatosis via longitudinal data from large samples is expected.

Acknowledgments

We thank Professor Alan C. Zheng for his help in language editing.

Author Contributions

FH designed the study; BC and YS wrote the manuscript; DZ and JY revised the manuscript.

Funding

This work was funded by grants from the National Natural Science Foundation of China (82003337), the China Postdoctoral Science Foundation (2020M683268), the Chongqing Natural Science Foundation (cstc2020jcyj-bshX0023), the Postdoctoral Foundation of Chongqing Medical University (R9001), and Funding for Key Disciplines of Third Affiliated Hospital of Chongqing Medical University (ZK201902).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Abdat R., Waldman R. A., de Bedout V., Czernik A., Mcleod M., King B., et al. (2020). Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series. J. Am. Acad. Dermatol. 83, 46–52. 10.1016/j.jaad.2020.01.089 [DOI] [PubMed] [Google Scholar]
  2. Agrawal A., Sridharan A., Prakash S., Agrawal H. (2012). Dendritic Cells and Aging: Consequences for Autoimmunity. Expert Rev. Clin. Immunol. 8, 73–80. 10.1586/eci.11.77 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Akdis C. A., Arkwright P. D., Brüggen M.-C., Busse W., Gadina M., Guttman-Yassky E., et al. (2020). Type 2 Immunity in the Skin and Lungs. Allergy 75, 1582–1605. 10.1111/all.14318 [DOI] [PubMed] [Google Scholar]
  4. Atmatzidis D. H., Lambert W. C., Lambert M. W. (2017). Langerhans Cell: Exciting Developments in Health and Disease. J. Eur. Acad. Dermatol. Venereol. 31, 1817–1824. 10.1111/jdv.14522 [DOI] [PubMed] [Google Scholar]
  5. Bağcı I. S., Horváth O. N., Ruzicka T., Sárdy M. (2017). Bullous Pemphigoid. Autoimmun. Rev. 16, 445–455. 10.1016/j.autrev.2017.03.010 [DOI] [PubMed] [Google Scholar]
  6. Bautista-Hernández L. A., Gómez-Olivares J. L., Buentello-Volante B., Bautista-de Lucio V. M. (2017). Fibroblasts: The Unknown Sentinels Eliciting Immune Responses against Microorganisms. Eur. J. Microbiol. Immunol. 7, 151–157. 10.1556/1886.2017.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bektas A., Schurman S. H., Sen R., Ferrucci L. (2017). Human T Cell Immunosenescence and Inflammation in Aging. J. Leukoc. Biol. 102, 977–988. 10.1189/jlb.3RI0716-335R [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Black A. P. B., Ardern-Jones M. R., Kasprowicz V., Bowness P., Jones L., Bailey A. S., et al. (2007). Human Keratinocyte Induction of Rapid Effector Function in Antigen-specific Memory CD4+ and CD8+ T Cells. Eur. J. Immunol. 37, 1485–1493. 10.1002/eji.200636915 [DOI] [PubMed] [Google Scholar]
  9. Bocheva G. S., Slominski R. M., Slominski A. T. (2021). Immunological Aspects of Skin Aging in Atopic Dermatitis. Int. J. Mol. Sci. 22, 5729. 10.3390/ijms22115729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Boehncke W.-H., Brembilla N. C. (2019). Autoreactive T-Lymphocytes in Inflammatory Skin Diseases. Front. Immunol. 10, 1198. 10.3389/fimmu.2019.01198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Boniface K., Bernard F.-X., Garcia M., Gurney A. L., Lecron J.-C., Morel F. (2005). IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes. J. Immunol. 174, 3695–3702. 10.4049/jimmunol.174.6.3695 [DOI] [PubMed] [Google Scholar]
  12. Boothby I. C., Kinet M. J., Boda D. P., Kwan E. Y., Clancy S., Cohen J. N., et al. (2021). Early-life Inflammation Primes a T Helper 2 Cell-Fibroblast Niche in Skin. Nature 599, 667–672. 10.1038/s41586-021-04044-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bracken S. J., Abraham S., MacLeod A. S. (2019). Autoimmune Theories of Chronic Spontaneous Urticaria. Front. Immunol. 10, 627. 10.3389/fimmu.2019.00627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brüggen M.-C., Bauer W. M., Reininger B., Clim E., Captarencu C., Steiner G. E., et al. (2016). In Situ Mapping of Innate Lymphoid Cells in Human Skin: Evidence for Remarkable Differences between Normal and Inflamed Skin. J. Invest. Dermatol. 136, 2396–2405. 10.1016/j.jid.2016.07.017 [DOI] [PubMed] [Google Scholar]
  15. Chen Q., Zhong H., Chen W. C., Zhai Z., Zhou Z., Song Z., et al. (2018). Different Expression Patterns of Plasma Th1-, Th2-, Th17- and Th22-Related Cytokines Correlate with Serum Autoreactivity and Allergen Sensitivity in Chronic Spontaneous Urticaria. J. Eur. Acad. Dermatol. Venereol. 32, 441–448. 10.1111/jdv.14541 [DOI] [PubMed] [Google Scholar]
  16. Chen Y.-J., Wu C. Y., Shen J. L., Chen T. T., Chang Y. T. (2012). Cancer Risk in Patients with Chronic Urticaria. Arch. Dermatol. 148, 103–108. 10.1001/archdermatol.2011.682 [DOI] [PubMed] [Google Scholar]
  17. Chung C. L., Lawrence I., Hoffman M., Elgindi D., Nadhan K., Potnis M., et al. (2019). Topical Rapamycin Reduces Markers of Senescence and Aging in Human Skin: an Exploratory, Prospective, Randomized Trial. GeroScience 41, 861–869. 10.1007/s11357-019-00113-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cole M. A., Quan T., Voorhees J. J., Fisher G. J. (2018). Extracellular Matrix Regulation of Fibroblast Function: Redefining Our Perspective on Skin Aging. J. Cel Commun. Signal. 12, 35–43. 10.1007/s12079-018-0459-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Collin M., Bigley V. (2018). Human Dendritic Cell Subsets: an Update. Immunology 154, 3–20. 10.1111/imm.12888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Correia-Melo C., Birch J., Fielder E., Rahmatika D., Taylor J., Chapman J., et al. (2019). Rapamycin Improves Healthspan but Not Inflammaging in Nfκb1 −/− Mice. Aging cell 18, e12882. 10.1111/acel.12882 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Corsini E., Racchi M., Lucchi L., Donetti E., Bedoni M., Viviani B., et al. (2009). Skin Immunosenescence: Decreased Receptor for Activated C Kinase-1 Expression Correlates with Defective Tumour Necrosis Factor-α Production in Epidermal Cells. Br. J. Dermatol. 160, 16–25. 10.1111/j.1365-2133.2008.08885.x [DOI] [PubMed] [Google Scholar]
  22. Cozzani E., Gasparini G., Di Zenzo G., Parodi A. (2018). Immunoglobulin E and Bullous Pemphigoid. Eur. J. Dermatol. 28, 440–448. 10.1684/ejd.2018.3366 [DOI] [PubMed] [Google Scholar]
  23. Debes G. F., McGettigan S. E. (2019). Skin-Associated B Cells in Health and Inflammation. J. Immunol. 202, 1659–1666. 10.4049/jimmunol.1801211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Deng C., Peng N., Tang Y., Yu N., Wang C., Cai X., et al. (2021). Roles of IL-25 in Type 2 Inflammation and Autoimmune Pathogenesis. Front. Immunol. 12, 691559. 10.3389/fimmu.2021.691559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Elias P. M., Steinhoff M. (2008). "Outside-to-Inside" (And Now Back to "Outside") Pathogenic Mechanisms in Atopic Dermatitis. J. Invest. Dermatol. 128, 1067–1070. 10.1038/jid.2008.88 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fang H., Li Q., Wang G. (2020). The Role of T Cells in Pemphigus Vulgaris and Bullous Pemphigoid. Autoimmun. Rev. 19, 102661. 10.1016/j.autrev.2020.102661 [DOI] [PubMed] [Google Scholar]
  27. Farage M. A., Miller K. W., Berardesca E., Maibach H. I. (2009). Clinical Implications of Aging Skin. Am. J. Clin. Dermatol. 10, 73–86. 10.2165/00128071-200910020-00001 [DOI] [PubMed] [Google Scholar]
  28. Ferris L. K., Mburu Y. K., Mathers A. R., Fluharty E. R., Larregina A. T., Ferris R. L., et al. (2013). Human Beta-Defensin 3 Induces Maturation of Human Langerhans Cell-like Dendritic Cells: an Antimicrobial Peptide that Functions as an Endogenous Adjuvant. J. Invest. Dermatol. 133, 460–468. 10.1038/jid.2012.319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fitsiou E., Pulido T., Campisi J., Alimirah F., Demaria M. (2021). Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging. J. Invest. Dermatol. 141 (4S), 1119–1126. 10.1016/j.jid.2020.09.031 [DOI] [PubMed] [Google Scholar]
  30. Gandhi N. A., Bennett B. L., Graham N. M. H., Pirozzi G., Stahl N., Yancopoulos G. D. (2016). Targeting Key Proximal Drivers of Type 2 Inflammation in Disease. Nat. Rev. Drug Discov. 15, 35–50. 10.1038/nrd4624 [DOI] [PubMed] [Google Scholar]
  31. Geherin S. A., Fintushel S. R., Lee M. H., Wilson R. P., Patel R. T., Alt C., et al. (2012). The Skin, a Novel Niche for Recirculating B Cells. J. Immunol. 188, 6027–6035. 10.4049/jimmunol.1102639 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ghetti M., Topouzi H., Theocharidis G., Papa V., Williams G., Bondioli E., et al. (2018). Subpopulations of Dermal Skin Fibroblasts Secrete Distinct Extracellular Matrix: Implications for Using Skin Substitutes in the Clinic. Br. J. Dermatol. 179, 381–393. 10.1111/bjd.16255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ghosh K., Capell B. C. (2016). The Senescence-Associated Secretory Phenotype: Critical Effector in Skin Cancer and Aging. J. Invest. Dermatol. 136, 2133–2139. 10.1016/j.jid.2016.06.621 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Gittler J. K., Shemer A., Suárez-Fariñas M., Fuentes-Duculan J., Gulewicz K. J., Wang C. Q. F., et al. (2012). Progressive Activation of TH2/TH22 Cytokines and Selective Epidermal Proteins Characterizes Acute and Chronic Atopic Dermatitis. J. Allergy Clin. Immunol. 130, 1344–1354. 10.1016/j.jaci.2012.07.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Haniffa M. A., Wang X.-N., Holtick U., Rae M., Isaacs J. D., Dickinson A. M., et al. (2007). Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells. J. Immunol. 179, 1595–1604. 10.4049/jimmunol.179.3.1595 [DOI] [PubMed] [Google Scholar]
  36. Hashimoto T., Kursewicz C. D., Fayne R. A., Nanda S., Shah S. M., Nattkemper L., et al. (2020). Pathophysiologic Mechanisms of Itch in Bullous Pemphigoid. J. Am. Acad. Dermatol. 83, 53–62. 10.1016/j.jaad.2019.07.060 [DOI] [PubMed] [Google Scholar]
  37. Hu L., Mauro T. M., Dang E., Man G., Zhang J., Lee D., et al. (2017). Epidermal Dysfunction Leads to an Age-Associated Increase in Levels of Serum Inflammatory Cytokines. J. Invest. Dermatol. 137, 1277–1285. 10.1016/j.jid.2017.01.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kay A. B., Clark P., Maurer M., Ying S. (2015). Elevations in T-Helper-2-Initiating Cytokines (Interleukin-33, Interleukin-25 and Thymic Stromal Lymphopoietin) in Lesional Skin from Chronic Spontaneous ('idiopathic') Urticaria. Br. J. Dermatol. 172, 1294–1302. 10.1111/bjd.13621 [DOI] [PubMed] [Google Scholar]
  39. Kim B. S., Siracusa M. C., Saenz S. A., Noti M., Monticelli L. A., Sonnenberg G. F., et al. (2013). TSLP Elicits IL-33-independent Innate Lymphoid Cell Responses to Promote Skin Inflammation. Sci. Transl. Med. 5, 170ra16. 10.1126/scitranslmed.3005374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Köllisch G., Kalali B. N., Voelcker V., Wallich R., Behrendt H., Ring J., et al. (2005). Various Members of the Toll-like Receptor Family Contribute to the Innate Immune Response of Human Epidermal Keratinocytes. Immunology 114, 531–541. 10.1111/j.1365-2567.2005.02122.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Kolter J., Feuerstein R., Zeis P., Hagemeyer N., Paterson N., d’Errico P., et al. (2019). A Subset of Skin Macrophages Contributes to the Surveillance and Regeneration of Local Nerves. Immunity 50, 1482–1497. e7. 10.1016/j.immuni.2019.05.009 [DOI] [PubMed] [Google Scholar]
  42. Lages C. S., Suffia I., Velilla P. A., Huang B., Warshaw G., Hildeman D. A., et al. (2008). Functional Regulatory T Cells Accumulate in Aged Hosts and Promote Chronic Infectious Disease Reactivation. J. Immunol. 181, 1835–1848. 10.4049/jimmunol.181.3.1835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Li H., Li H., Huo R., Wu P., Shen Z., Xu H., et al. (2017). Cyr61/CCN1 Induces CCL20 Production by Keratinocyte via Activating P38 and JNK/AP-1 Pathway in Psoriasis. J. Dermatol. Sci. 88, 46–56. 10.1016/j.jdermsci.2017.05.018 [DOI] [PubMed] [Google Scholar]
  44. Lloyd-Lavery A., Solman L., Grindlay D. J. C., Rogers N. K., Thomas K. S., Harman K. E. (20192016). What's New in Atopic Eczema? an Analysis of Systematic Reviews Published in 2016. Part 2: Epidemiology, Aetiology and Risk factorsPart 2: Epidemiology, Aetiology and Risk Factors. Clin. Exp. Dermatol. 44, 370–375. 10.1111/ced.13853 [DOI] [PubMed] [Google Scholar]
  45. Lopes-Paciencia S., Saint-Germain E., Rowell M.-C., Ruiz A. F., Kalegari P., Ferbeyre G. (2019). The Senescence-Associated Secretory Phenotype and its Regulation. Cytokine 117, 15–22. 10.1016/j.cyto.2019.01.013 [DOI] [PubMed] [Google Scholar]
  46. Mackay L. K., Rahimpour A., Ma J. Z., Collins N., Stock A. T., Hafon M.-L., et al. (2013). The Developmental Pathway for CD103+CD8+ Tissue-Resident Memory T Cells of Skin. Nat. Immunol. 14, 1294–1301. 10.1038/ni.2744 [DOI] [PubMed] [Google Scholar]
  47. Magen E., Mishal J., Schlesinger M. (2013). Clinical and Laboratory Features of Chronic Idiopathic Urticaria in the Elderly. Int. J. Dermatol. 52, 1387–1391. 10.1111/ijd.12109 [DOI] [PubMed] [Google Scholar]
  48. McLellan A. D., Heiser A., Sorg R. V., Fearnley D. B., Hart D. N. J. (1998). Dermal Dendritic Cells Associated with T Lymphocytes in normal Human Skin Display an Activated Phenotype. J. Invest. Dermatol. 111, 841–849. 10.1046/j.1523-1747.1998.00375.x [DOI] [PubMed] [Google Scholar]
  49. Mediaty A., Neuber K. (2005). Total and Specific Serum IgE Decreases with Age in Patients with Allergic Rhinitis, Asthma and Insect Allergy but Not in Patients with Atopic Dermatitis. Immun. Ageing 2, 9. 10.1186/1742-4933-2-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Messingham K. N., Crowe T. P., Fairley J. A. (2019). The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid. Front. Immunol. 10, 2331. 10.3389/fimmu.2019.02331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Miller L. S., Modlin R. L. (2007). Human Keratinocyte Toll-like Receptors Promote Distinct Immune Responses. J. Invest. Dermatol. 127, 262–263. 10.1038/sj.jid.5700559 [DOI] [PubMed] [Google Scholar]
  52. Nakahara T., Kido-Nakahara M., Tsuji G., Furue M. (2021). Basics and Recent Advances in the Pathophysiology of Atopic Dermatitis. J. Dermatol. 48, 130–139. 10.1111/1346-8138.15664 [DOI] [PubMed] [Google Scholar]
  53. Nguyen Q. P., Deng T. Z., Witherden D. A., Goldrath A. W. (2019). Origins of CD 4 + Circulating and Tissue-Resident Memory T-Cells. Immunology 157, 3–12. 10.1111/imm.13059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Nielsen M. M., Witherden D. A., Havran W. L. (2017). Γδ T Cells in Homeostasis and Host Defence of Epithelial Barrier Tissues. Nat. Rev. Immunol. 17, 733–745. 10.1038/nri.2017.101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Noe M. H., Messingham K., Aust S., Gross S., Fairley J. A. (2015). Bullous Pemphigoid Patients Exhibit Increased Markers of immunosenescence.2015 Annual Meeting Of the SID . Atlanta, GA, USA. 6–9th May 2015, Meeting Program, S1:LB738. [Google Scholar]
  56. Otsuka A., Kabashima K. (2015). Mast Cells and Basophils in Cutaneous Immune Responses. Allergy 70, 131–140. 10.1111/all.12526 [DOI] [PubMed] [Google Scholar]
  57. Partridge L., Fuentealba M., Kennedy B. K. (2020). The Quest to Slow Ageing through Drug Discovery. Nat. Rev. Drug Discov. 19, 513–532. 10.1038/s41573-020-0067-7 [DOI] [PubMed] [Google Scholar]
  58. Pezzolo E., Naldi L. (2020). Epidemiology of Major Chronic Inflammatory Immune-Related Skin Diseases in 2019. Expert Rev. Clin. Immunol. 16, 155–166. 10.1080/1744666X.2020.1719833 [DOI] [PubMed] [Google Scholar]
  59. Pietkiewicz P., Gornowicz-Porowska J., Bowszyc-Dmochowska M., Bartkiewicz P., Dmochowski M. (2016). Bullous Pemphigoid and Neurodegenerative Diseases: a Study in a Setting of a Central European university Dermatology Department. Aging Clin. Exp. Res. 28, 659–663. 10.1007/s40520-015-0459-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Pilkington S. M., Barron M. J., Watson R. E. B., Griffiths C. E. M., Bulfone-Paus S. (2019). Aged Human Skin Accumulates Mast Cells with Altered Functionality that Localize to Macrophages and Vasoactive Intestinal Peptide-Positive Nerve Fibres. Br. J. Dermatol. 180, 849–858. 10.1111/bjd.17268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Pilkington S. M., Bulfone-Paus S., Griffiths C. E. M., Watson R. E. B. (2021). Inflammaging and the Skin. J. Invest. Dermatol. 141, 1087–1095. 10.1016/j.jid.2020.11.006 [DOI] [PubMed] [Google Scholar]
  62. Pilkington S. M., Dearman R. J., Kimber I., Griffiths C. E. M. (2018a). Langerhans Cells Express Human β-defensin 3: Relevance for Immunity during Skin Ageing. Br. J. Dermatol. 179, 1170–1171. 10.1111/bjd.16770 [DOI] [PubMed] [Google Scholar]
  63. Pilkington S. M., Ogden S., Eaton L. H., Dearman R. J., Kimber I., Griffiths C. E. M. (2018b). Lower Levels of Interleukin-1β Gene Expression Are Associated with Impaired Langerhans' Cell Migration in Aged Human Skin. Immunology 153, 60–70. 10.1111/imm.12810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Pinti M., Appay V., Campisi J., Frasca D., Fülöp T., Sauce D., et al. (2016). Aging of the Immune System: Focus on Inflammation and Vaccination. Eur. J. Immunol. 46, 2286–2301. 10.1002/eji.201546178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Qin D., Ren R., Jia C., Lu Y., Yang Q., Chen L., et al. (2018). Rapamycin Protects Skin Fibroblasts from Ultraviolet B-Induced Photoaging by Suppressing the Production of Reactive Oxygen Species. Cell Physiol Biochem 46, 1849–1860. 10.1159/000489369 [DOI] [PubMed] [Google Scholar]
  66. Rafei-Shamsabadi D. A., Klose C. S. N., Halim T. Y. F., Tanriver Y., Jakob T. (2019). Context Dependent Role of Type 2 Innate Lymphoid Cells in Allergic Skin Inflammation. Front. Immunol. 10, 2591. 10.3389/fimmu.2019.02591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Rijken F., Kiekens R. C. M., Bruijnzeel P. L. B. (2005). Skin-infiltrating Neutrophils Following Exposure to Solar-Simulated Radiation Could Play an Important Role in Photoageing of Human Skin. Br. J. Dermatol. 152, 321–328. 10.1111/j.1365-2133.2004.06335.x [DOI] [PubMed] [Google Scholar]
  68. Sánchez-Borges M., Capriles-Hulett A., Caballero-Fonseca F., González-Aveledo L. (2018). Biomarkers of Treatment Efficacy in Patients with Chronic Spontaneous Urticaria. Eur. Ann. Allergy Clin. Immunol. 50, 5–9. 10.23822/EurAnnACI.1764-1489.24 [DOI] [PubMed] [Google Scholar]
  69. Scharschmidt T. C., Vasquez K. S., Pauli M. L., Leitner E. G., Chu K., Truong H.-A., et al. (2017). Commensal Microbes and Hair Follicle Morphogenesis Coordinately Drive Treg Migration into Neonatal Skin. Cell Host & Microbe 21, 467–477. e5. 10.1016/j.chom.2017.03.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Schwarz A., Bruhs A., Schwarz T. (2017). The Short-Chain Fatty Acid Sodium Butyrate Functions as a Regulator of the Skin Immune System. J. Invest. Dermatol. 137, 855–864. 10.1016/j.jid.2016.11.014 [DOI] [PubMed] [Google Scholar]
  71. Sperling T., Ołdak M., Walch-Rückheim B., Wickenhauser C., Doorbar J., Pfister H., et al. (2012). Human Papillomavirus Type 8 Interferes with a Novel C/EBPβ-Mediated Mechanism of Keratinocyte CCL20 Chemokine Expression and Langerhans Cell Migration. Plos Pathog. 8, e1002833. 10.1371/journal.ppat.1002833 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Suggs A., Oyetakin-White P., Baron E. (2014). Effect of Botanicals on Inflammation and Skin Aging: Analyzing the Evidence. Inflamm. Allergy-Drug Targets 13, 168–176. 10.2174/1871528113666140526163052 [DOI] [PubMed] [Google Scholar]
  73. Tanei R., Hasegawa Y. (2016). Atopic Dermatitis in Older Adults: A Viewpoint from Geriatric Dermatology. Geriatr. Gerontol. Int. 16 (Suppl. 1), 75–86. 10.1111/ggi.12771 [DOI] [PubMed] [Google Scholar]
  74. Tanei R., Hasegawa Y., Sawabe M. (2013). Abundant Immunoglobulin E-Positive Cells in Skin Lesions Support an Allergic Etiology of Atopic Dermatitis in the Elderly. J. Eur. Acad. Dermatol. Venereol. 27, 952–960. 10.1111/j.1468-3083.2012.04612.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Thomas R., Wang W., Su D.-M. (2020). Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immun. Ageing 17, 2. 10.1186/s12979-020-0173-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Tsuboi I., Harada T., Hirabayashi Y., Kanno J., Inoue T., Aizawa S. (2012). Age-related Decline of Mast Cell Regeneration in Senescence-Accelerated Mice (SAMP1) after Chemical Myeloablation Due to Senescent Stromal Cell Impairment. Exp. Biol. Med. (Maywood) 237, 1289–1297. 10.1258/ebm.2012.012158 [DOI] [PubMed] [Google Scholar]
  77. Vadasz Z., Toubi E. (2015). The Role of Increased T Helper Cell 2 Cytokine Expression in Skin Weals of Chronic Spontaneous Urticaria: Are They Always Activating Cytokines. Br. J. Dermatol. 172, 1185–1186. 10.1111/bjd.13784 [DOI] [PubMed] [Google Scholar]
  78. Wasko R. R., Horsley V. (2019). Thin Skinned: Aged Adipocyte Atrophy Impacts Innate Immunity. Trends Immunology 40, 175–177. 10.1016/j.it.2019.01.009 [DOI] [PubMed] [Google Scholar]
  79. Watanabe R., Gehad A., Yang C., Scott L. L., Teague J. E., Schlapbach C., et al. (2015). Human Skin Is Protected by Four Functionally and Phenotypically Discrete Populations of Resident and Recirculating Memory T Cells. Sci. Transl. Med. 7, 279ra39. 10.1126/scitranslmed.3010302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. West H. C., Bennett C. L. (2018). Redefining the Role of Langerhans Cells as Immune Regulators within the Skin. Front. Immunol. 8, 1941. 10.3389/fimmu.2017.01941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Williamson S., Merritt J., De Benedetto A. (2020). Atopic Dermatitis in the Elderly: a Review of Clinical and Pathophysiological Hallmarks. Br. J. Dermatol. 182, 47–54. 10.1111/bjd.17896 [DOI] [PubMed] [Google Scholar]
  82. Wittmann M., McGonagle D., Werfel T. (2014). Cytokines as Therapeutic Targets in Skin Inflammation. Cytokine Growth Factor. Rev. 25, 443–451. 10.1016/j.cytogfr.2014.07.008 [DOI] [PubMed] [Google Scholar]
  83. Wlaschek M., Maity P., Makrantonaki E., Scharffetter-Kochanek K. (2021). Connective Tissue and Fibroblast Senescence in Skin Aging. J. Invest. Dermatol. 141, 985–992. 10.1016/j.jid.2020.11.010 [DOI] [PubMed] [Google Scholar]
  84. Yaar M., Gilchrest B. A. r. A. (1987). Bullous Pemphigoid: Disease of the Aging Immune System. Clin. Dermatol. 5, 135–145. 10.1016/0738-081x(87)90058-7 [DOI] [PubMed] [Google Scholar]
  85. Yamazaki S., Nishioka A., Kasuya S., Ohkura N., Hemmi H., Kaisho T., et al. (2014). Homeostasis of Thymus-Derived Foxp3+ Regulatory T Cells Is Controlled by Ultraviolet B Exposure in the Skin. J. Immunol. 193, 5488–5497. 10.4049/jimmunol.1400985 [DOI] [PubMed] [Google Scholar]
  86. Ye L., Mauro T. M., Dang E., Wang G., Hu L. Z., Yu C., et al. (2019). Topical Applications of an Emollient Reduce Circulating Pro-inflammatory Cytokine Levels in Chronically Aged Humans: a Pilot Clinical Study. J. Eur. Acad. Dermatol. Venereol. 33, 2197–2201. 10.1111/jdv.15540 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Zbytek B., Janjetovic Z., Tuckey R. C., Zmijewski M. A., Sweatman T. W., Jones E., et al. (2008). 20-Hydroxyvitamin D3, a Product of Vitamin D3 Hydroxylation by Cytochrome P450scc, Stimulates Keratinocyte Differentiation. J. Invest. Dermatol. 128, 2271–2280. 10.1038/jid.2008.62 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Zhang L.-j., Guerrero-Juarez C. F., Hata T., Bapat S. P., Ramos R., Plikus M. V., et al. (2015). Dermal Adipocytes Protect against Invasive Staphylococcus aureus Skin Infection. Science 347, 67–71. 10.1126/science.1260972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Zhang L.-j., Chen S. X., Guerrero-Juarez C. F., Li F., Tong Y., Liang Y., et al. (2019). Age-Related Loss of Innate Immune Antimicrobial Function of Dermal Fat Is Mediated by Transforming Growth Factor Beta. Immunity 50, 121–136. e5. 10.1016/j.immuni.2018.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Zhou L., Leonard A., Pavel A. B., Malik K., Raja A., Glickman J., et al. (2019). Age-specific Changes in the Molecular Phenotype of Patients with Moderate-To-Severe Atopic Dermatitis. J. Allergy Clin. Immunol. 144, 144–156. 10.1016/j.jaci.2019.01.015 [DOI] [PubMed] [Google Scholar]
  91. Zouboulis C. C., Makrantonaki E. (2011). Clinical Aspects and Molecular Diagnostics of Skin Aging. Clin. Dermatol. 29, 3–14. 10.1016/j.clindermatol.2010.07.001 [DOI] [PubMed] [Google Scholar]
  92. Zuelgaray E., Boccara D., Ly Ka So S., Boismal F., Mimoun M., Bagot M., et al. (2019). Increased Expression of PD1 and CD39 on CD3+ CD4+ Skin T Cells in the Elderly. Exp. Dermatol. 28, 80–82. 10.1111/exd.13842 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Cell and Developmental Biology are provided here courtesy of Frontiers Media SA

RESOURCES